STUDY OF THE EXPRESSION OF MICRORNA 181A AND ITS TARGET GENES: BCL2 AND NOVA1 IN MULTIPLE MYELOMA | ||||
| ALEXMED ePosters | ||||
| Article 79, Volume 3, Issue 2, June 2021, Page 5-6 | ||||
| Document Type: Preliminary preprint short reports of original research | ||||
| DOI: 10.21608/alexpo.2021.62618.1120 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Yasmin Wagih Yakout 
| ||||
| Clinical and Chemical Pathology Department, Faculty of Medicine, Alexandria University, Egypt | ||||
| Abstract | ||||
| Multiple myeloma (MM) is a plasma cell neoplasm accounting for 10% of hematological malignancies. It is characterized by clonal proliferation of plasma cells in the bone marrow resulting in monoclonal M-protein production. This ultimately results in end organ damage presenting as: C (Hypercalcemia), R (Renal failure), A (Anemia), B (bone lesions). MM is characterized by its complex genetic landscape, that tends to change over time owing to additional events, as somatic mutations, epigenetic and chromosomal copy-number changes. The role of micro-RNAs, small non-coding RNAs, in myelomagenesis has been receiving increasing attention. They are found to manipulate the cross talk between myeloma cells and bone marrow micro-environment and thereby playing their role. Studies have shown that miR-181a may play a role in lymphocyte proliferation and differentiation into B cells. At the same time, it has been suggested that the expression of miR-181a is increased in MM. The complex relationship between miR-181a and the various clinical and pathological factors of MM disease is yet to be clarified. | ||||
| Keywords | ||||
| Multiple myeloma (MM); miR-181a; BCL2 and NOVA1 | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 164 |
||||
